JNPMEDI Selected for TIPS by Ministry of SMEs and Startups

19 Apr 2022 · 5 minutes read

JNPMEDI was selected as the Tech Incubator Program for Start-up (TIPS) by the Ministry of SMEs and Startups.


JNPMEDI was selected as the Tech Incubator Program for Start-up (TIPS) by the Ministry of SMEs and Startups. TIPS (Tech Incubator Program for Startup) is a "private investment-led technology start-up support program" in which the government and the private sector select promising startups with technology to lead the global market together and support about 500 million won in R&D costs for two years.

JNPMEDI is a startup in the digital healthcare sector and was selected for the 2022 TIPS program in recognition of its technology and global commercialization potential. In December last year, Kakao Ventures, Ajou IB Investment, and Murex Partners were evaluated as platform companies that will lead to changes in the domestic medical ecosystem and attracted seed investment worth 2 billion won. Through this investment in Tips, JNPMEDI plans to develop Decentralized Clinical Trials (DCTs) services. Due to the COVID-19 pandemic, non-face-to-face DCT is rapidly becoming the latest trend in overseas clinical trials.

Compared to traditional clinical trial methods, DCT is rapidly emerging as an alternative that can provide various benefits such as shortening the clinical period and cost to all involved, such as pharmaceutical companies, clinical trial centers, and clinical trial consignment institutions. Recently, the domestic Ministry of Food and Drug Safety has started to advance regulations due to changes in the clinical trial environment, and related markets are expected to open along with changes in the perception of DCT.

JNPMEDI aims to develop services that can perform patient-centered remote clinical trials without visiting medical institutions through the development of DCT-related functions such as △ eConsent and Identification △ Direct to Patient and △ Clinical Outcome Assessment.


Your Partner for a Successful Journey

JNPMEDI has been putting effort on bringing disruption on healthcare industry via integrating digital technologies to clinical research & trial operations.